Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in Adult Immunocompromised Patients: A Real-World Cohort Study.

IF 1.8
Drew W Charles, Yosra Alkabab, Divisha Sharma, Ruth O Adekunle, Jillian Catalano, Rachel Colven, Scott R Curry, Susan E Dorman, Eric G Meissner, Alexandra Mills, Logan Patterson, Charles S Teixeria, Robert Sean Tyler, Cassandra D Salgado, Courtney E Harris
{"title":"Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in Adult Immunocompromised Patients: A Real-World Cohort Study.","authors":"Drew W Charles, Yosra Alkabab, Divisha Sharma, Ruth O Adekunle, Jillian Catalano, Rachel Colven, Scott R Curry, Susan E Dorman, Eric G Meissner, Alexandra Mills, Logan Patterson, Charles S Teixeria, Robert Sean Tyler, Cassandra D Salgado, Courtney E Harris","doi":"10.1016/j.amjms.2026.10.011","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Plasma metagenomic next generation sequencing (mNGS) enables noninvasive pathogen detection independent of organism viability. Although analytic performance has been described, the real-world clinical impact in immunocompromised hosts remains incompletely defined.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of immunocompromised adults undergoing plasma mNGS testing from January 2022 through November 2024 at the Medical University of South Carolina. Immunocompromised conditions included solid organ transplantation, hematopoietic stem cell transplantation, active hematologic malignancy, HIV, or biologic immunosuppressants. Clinical impact was adjudicated by infectious disease physicians as positive, negative, or neutral. Positive results were classified as definite, probable, possible, or unlikely infectious based on clinical correlation and concordance with conventional microbiologic testing (CMT).</p><p><strong>Results: </strong>Ninety-eight patients were included (median age 60 years [range 18-76]; 63% male), including solid organ transplant (31%), hematopoietic stem cell transplant (8%), HIV (13%), active malignancy (42%), corticosteroids (3%), and biologic therapy (10%). At testing, 85% were receiving antimicrobials and 88% were hospitalized. Plasma mNGS was positive in 62% of cases, with CMT concordance in 30%. Thirty-two percent of tests had positive clinical impact, identifying unrecognized infection or antimicrobial optimization. Sixty-six percent had no treatment impact and 2% had potential negative impact. More than half of discordant positives were deemed possible or unlikely infections. False-negative cases included invasive mold and nontuberculous mycobacterial infections.</p><p><strong>Conclusions: </strong>In this antimicrobial-exposed immunocompromised cohort, plasma mNGS frequently detected organisms but less often influenced clinical management. Discordant positives were common, and false negatives occurred in selected syndromes, supporting cautious interpretation and stewardship-guided use.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2026.10.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Plasma metagenomic next generation sequencing (mNGS) enables noninvasive pathogen detection independent of organism viability. Although analytic performance has been described, the real-world clinical impact in immunocompromised hosts remains incompletely defined.

Methods: We conducted a retrospective cohort study of immunocompromised adults undergoing plasma mNGS testing from January 2022 through November 2024 at the Medical University of South Carolina. Immunocompromised conditions included solid organ transplantation, hematopoietic stem cell transplantation, active hematologic malignancy, HIV, or biologic immunosuppressants. Clinical impact was adjudicated by infectious disease physicians as positive, negative, or neutral. Positive results were classified as definite, probable, possible, or unlikely infectious based on clinical correlation and concordance with conventional microbiologic testing (CMT).

Results: Ninety-eight patients were included (median age 60 years [range 18-76]; 63% male), including solid organ transplant (31%), hematopoietic stem cell transplant (8%), HIV (13%), active malignancy (42%), corticosteroids (3%), and biologic therapy (10%). At testing, 85% were receiving antimicrobials and 88% were hospitalized. Plasma mNGS was positive in 62% of cases, with CMT concordance in 30%. Thirty-two percent of tests had positive clinical impact, identifying unrecognized infection or antimicrobial optimization. Sixty-six percent had no treatment impact and 2% had potential negative impact. More than half of discordant positives were deemed possible or unlikely infections. False-negative cases included invasive mold and nontuberculous mycobacterial infections.

Conclusions: In this antimicrobial-exposed immunocompromised cohort, plasma mNGS frequently detected organisms but less often influenced clinical management. Discordant positives were common, and false negatives occurred in selected syndromes, supporting cautious interpretation and stewardship-guided use.

血浆微生物无细胞DNA测序在成人免疫功能低下患者中的临床应用:一项真实世界队列研究。
背景:血浆宏基因组下一代测序(mNGS)能够独立于生物体活力进行无创病原体检测。虽然分析性能已经描述,现实世界的临床影响免疫功能低下的宿主仍然不完全确定。方法:我们对2022年1月至2024年11月在南卡罗来纳医科大学接受血浆mNGS检测的免疫功能低下成人进行了回顾性队列研究。免疫功能低下的情况包括实体器官移植、造血干细胞移植、活动性血液恶性肿瘤、HIV或生物免疫抑制剂。临床影响由传染病医生判定为积极、消极或中性。阳性结果根据临床相关性和与常规微生物学检测(CMT)的一致性分为确定、可能、可能或不太可能感染。结果:纳入98例患者(中位年龄60岁[范围18-76岁],男性63%),包括实体器官移植(31%)、造血干细胞移植(8%)、HIV(13%)、活动性恶性肿瘤(42%)、皮质类固醇(3%)和生物治疗(10%)。在检测时,85%的人正在接受抗微生物药物治疗,88%的人住院。62%的患者血浆mNGS阳性,30%的患者CMT一致。32%的测试具有积极的临床影响,确定了未被识别的感染或抗菌优化。66%的人没有治疗效果,2%的人有潜在的负面影响。超过一半的不一致阳性结果被认为可能或不太可能感染。假阴性病例包括侵袭性霉菌和非结核分枝杆菌感染。结论:在这个暴露于抗微生物药物的免疫功能低下队列中,血浆mNGS经常检测到微生物,但较少影响临床管理。不一致的阳性是常见的,在某些综合征中出现假阴性,支持谨慎解释和管理指导使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书